Drugs / BAC
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT02886494 Comparator | Dec 2016 → Nov 2018 | Alzheimer disease, vascular dementia | Charsire Biotechnology Corp. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02886494 ↗ |
| Route | Topical | “BAC, topical application on external nasal skin, scalp, and neck, 2 times daily, 30 g/day for 12 weeks” NCT02886494 ↗ |